Agios Pharmaceuticals IncAGIO
Price$33.25Intrinsic value$59.2678% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $98.3M+169.4% YoYTTM through 30 Jun 2026
Net Income -$411.3M-161.0% YoYTTM through 30 Jun 2026
Free Cash Flow -$365.3MTTM through 30 Jun 2026

Margins

Current
Gross Margin93.6%
EBITDA Margin-458.6%
Operating Margin-530.3%
Net Margin-418.2%

Returns

-8.9%ROE
-8.3%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio14.19x
Net Debt-$737Mnet cash position
Cash & Equivalents$99.6M

Quality Metrics

Altman Z-Score13.66
Piotroski F-Score2 / 9
FCF Margin-371.4%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $54M
Diluted EPS-$7.01TTM
'19'20'21'22'23'24'25
FY2025: $-7.12

Dividend

No dividend

Capital Allocation

Capex Intensity4.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.